WPD Pharmaceuticals IncCanadian Securities Exchange:WBIOView on OTC Pink - Current Information
- LAST PRICE0.0050
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots0.0050/ 477
- Open / Previous Close--- / 0.0050
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
WPD Pharmaceuticals Inc | 579.9K | -4.0x | --- |
Mydecine Innovations Group Inc | 617.6K | 0.0x | --- |
Chitogenx Inc | 415.7K | -0.2x | --- |
Albert Labs International Corp | 372.1K | -0.1x | --- |
Many Bright Ideas Technologies Inc | 228.9K | -3.3x | --- |
Lophos Holdings Inc | 858.6K | -0.7x | --- |
Company Information
WPD Pharmaceuticals Inc. is a Canada-based clinical-stage pharmaceutical company, with a focus on glioblastoma cancer (GBM) and other brain tumor programs. The Company is a biotechnology research and development company with a focus on oncology, namely research and development of medicinal products involving biological compounds and small molecules. It has four novel drug candidates with one in clinical development stage and three in pre-clinical development. It operates its business primarily through WPD Poland, a subsidiary of and the operating branch of the Company. Its portfolio includes WPD101, Berubicin, and WPD103. WPD101 is a family of biopharmaceuticals in preclinical stages of development for targeted treatment of brain tumors with a global license. Berubicin is an anthracycline proven to cross the blood-brain barrier and able to reach brain tumors.
Contact Information
- Headquarters
- 750 West Pender Street, Suite 401VANCOUVER, BC, Canada V6C 2T7
- Phone
- 604-561-2687
- Fax
- 604-565-3332
Executives
- Chief Executive Officer
- Mariusz Olejniczak
- Director
- Romuald Harwas
- Independent Director
- Constantine Carmichel
- Independent Director
- Nick Luksha
- Independent Director
- Peter Novak
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $579.9K |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 116.0M |
WPD Pharmaceuticals Inc does not pay a dividend. | |
Beta | --- |
EPS | $0.00 |
Book Value | $0.00 |
P/E Ratio | -4.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | 13.5x |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
